Want to see TSE:CRON full AI Analyst Report?
CRON Stock Chart & Stats
C$3.97
C$0.09(2.27%)
At close: 4:00 PM EDT
C$3.97
C$0.09(2.27%)
Day’s Range― - ―
52-Week RangeC$3.23 - C$4.66
Previous CloseN/A
Volume145.76K
Average Volume (3M)113.79K
Market Cap
C$1.61B
Enterprise ValueC$410.50
Total Cash (Recent Filing)C$797.02M
Total Debt (Recent Filing)C$1.29M
Price to Earnings (P/E)17.1
Beta1.26
Next Earnings
Nov 11, 2026EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.19
Shares Outstanding368,412,870
10 Day Avg. Volume99,052
30 Day Avg. Volume113,794
Financial Highlights & Ratios
PEG Ratio0.83
Price to Book (P/B)0.92
Price to Sales (P/S)6.74
P/FCF Ratio6.63K
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$4.73Price Target Upside19.02% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.15
Revenue Forecast (FY)C$199.00M
Bulls Say, Bears Say
Bulls Say
Revenue And EBITDA GrowthStrong revenue growth and expanding adjusted EBITDA indicate improving demand, product traction and operating leverage. If sustained across multiple periods, this momentum could strengthen Cronos’s ability to fund growth and move toward consistent profitability.
Conservative Balance SheetMinimal leverage materially reduces refinancing risk and interest burden, giving Cronos flexibility to withstand cannabis-market volatility. The strong capital base also supports investment in capacity, brands and strategic opportunities without relying heavily on external financing.
Brand And International TractionOutperformance versus the Canadian category and rapid international growth suggest Cronos is building differentiated brands rather than relying only on commodity volume. Broader geographic reach can diversify revenue and improve long-term market access.
Bears Say
Profitability Not Yet ProvenThe operating turnaround is encouraging, but persistent or recent losses mean earnings quality and profitability durability remain unproven. Cronos must sustain revenue growth, gross margin and cost discipline before investors can rely on recurring bottom-line earnings.
Margin VolatilityDependence on harvest conditions and shifting product or geographic mix can make gross profit less predictable. Margin variability may complicate planning and weaken cash-generation consistency, particularly if favorable seasonal or premium-market effects reverse.
Regulatory Exposure In IsraelIsrael is a key growth market, so an adverse regulatory finding could restrict imports, increase costs or disrupt Cronos’s competitive position. The investigation adds structural uncertainty to a business that has otherwise delivered repeated record performance there.
Cronos Group News
CRON FAQ
What was Cronos Group (US)’s price range in the past 12 months?
Cronos Group (US) lowest stock price was C$3.23 and its highest was C$4.66 in the past 12 months.
What is Cronos Group (US)’s market cap?
Cronos Group (US)’s market cap is C$1.61B.
When is Cronos Group (US)’s upcoming earnings report date?
Cronos Group (US)’s upcoming earnings report date is Nov 11, 2026 which is in 84 days.
How were Cronos Group (US)’s earnings last quarter?
Cronos Group (US) released its earnings results on Aug 06, 2026. The company reported C$0.125 earnings per share for the quarter, beating the consensus estimate of C$0.014 by C$0.111.
Is Cronos Group (US) overvalued?
According to Wall Street analysts Cronos Group (US)’s price is currently Undervalued.
Does Cronos Group (US) pay dividends?
Cronos Group (US) does not currently pay dividends.
What is Cronos Group (US)’s EPS estimate?
Cronos Group (US)’s EPS estimate is 0.03.
How many shares outstanding does Cronos Group (US) have?
Cronos Group (US) has 368,412,870 shares outstanding.
What happened to Cronos Group (US)’s price movement after its last earnings report?
Cronos Group (US) reported an EPS of C$0.125 in its last earnings report, beating expectations of C$0.014. Following the earnings report the stock price went up 13.684%.
Which hedge fund is a major shareholder of Cronos Group (US)?
Currently, no hedge funds are holding shares in TSE:CRON
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cronos Group Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
C$4.73 (19.02% Upside)
C$4.73 (19.02% Upside)
Blogger Sentiment
Bullish
TSE:CRON Sentiment 86%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.4%
Last 30 Days ▲ 9.0%
Last 30 Days ▲ 9.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
35.74%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
0.39%
Trailing 12-Months
Company Description
Cronos Group (US)
Cronos Group Inc. functions as a diversified global cannabinoid enterprise. Within the United States, it manufactures, promotes, and distributes a variety of hemp-derived supplements and cosmetic products. These items are available under its Lord Jones and Happy Dance brands through online sales, traditional retail, and hospitality partner networks. The company also plays a significant role in the cultivation, production, and commercialization of cannabis and cannabis-infused products for both medicinal and adult-use sectors. Its comprehensive product offerings encompass dried cannabis flower, pre-rolled joints, edibles, concentrated forms, and cannabis extracts. These are distributed via wholesale partnerships and direct-to-consumer channels, prominently featuring its wellness platform, PEACE NATURALS, and its adult-use brand, Spinach. Moreover, Cronos Group exports dried cannabis and cannabis oils to international markets including Germany, Israel, and Australia. Established in 2012, the company maintains its corporate headquarters in Toronto, Canada.
CRON Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a broadly positive operational and financial picture: record revenue, gross profit, and adjusted EBITDA, strong brand performance (notably Spinach), meaningful international growth (Israel and Germany), and a robust cash position. Key risks and headwinds include a new anti-dumping investigation in Israel, modest OpEx increases, margin variability tied to seasonality and mix, and timing uncertainty around the CanAdelaar closing. On balance, the positive operational momentum and strong financials outweigh the highlighted risks.View all TSE:CRON earnings summariesCRON Stock 12 Month Forecast
Average Price Target
C$4.73
▲(19.02% Upside)